
Manufacturers have selected AllianceRx Walgreens as their limited distribution drug partner for drugs that treat conditions such as myelofibrosis, cystic fibrosis, and non-metastatic castration-resistant prostate cancer.

Manufacturers have selected AllianceRx Walgreens as their limited distribution drug partner for drugs that treat conditions such as myelofibrosis, cystic fibrosis, and non-metastatic castration-resistant prostate cancer.

An effective treatment plan for squamous cell carcinoma best undertaken by a group of practitioners.

The CDC has reported 34800 new cancer diagnoses linked to HPV annually, and the virus is predicted to account for more than 90% of all cervical and anal cancers, more than 60% of all penile cancers, and 70% of all oral cancers.

Top news of the day from across the health care landscape.

Girish Dighe, PharmD, MS, explains why it's important to understand more than just the revenue integrity piece of the puzzle.

Members of the former International Academy of Compounding Pharmacists voted in November 2019 to change the association’s name to the Alliance for Pharmacy Compounding.

Deferasirox is indicated for treating chronic iron overload caused by repeated blood transfusions in patients age 2 years and older.

The Prescription Drug User Fee Act date, the FDA action data for this supplemental application, is scheduled for the second quarter of 2020.

A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.

Annoying work habits can set the tone for lower productivity and teamwork in the pharmacy.

Researchers investigate whether on-demand pre-exposure prophylaxis was similarly effective among individuals with lower exposure to HIV risk.

The treatment is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, according to Novo Nordisk.

According to the study authors, such “anti-austerity agents” represent a promising approach to cancer chemotherapy.

Could tadalafil be causing a patient to feel dizzy?

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times

The study led to insight on the process of tuberculosis bacillus infection as well as a potential drug treatment.

At the recent ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada, 3 speakers discussed new developments in influenza management.

The bill would have given the state's superintendent of insurance licensing and regulatory authority over pharmacy benefit managers (PBMs).1

Top news of the day from across the health care landscape.

Novadoz Pharmaceuticals, who markets the product, has commenced shipping of the drug, available in bottles of 30 tablets.

You wrote to us, and we listened! Here are the top social comments for the 2019 year.

Study findings presented at the American Society of Nephrology’s Kidney Week 2019 suggest a link between chronic use of proton pump inhibitors and progression of kidney function decline in chronic kidney disease.

From newsworthy moments to groundbreaking research, these are the most popular articles published on Pharmacy Times® during 2019.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and Merck) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Stuck in the pharmacy during the New Year’s Eve festivities? This Pharmacy Times countdown has everything you need for celebrating the holiday with your pharmacy team.

Deeb Eid, PharmD, is creator of the Pharmacy Universe podcast on Spreaker. An associate professor and experiential coordinator at Ferris State University College of Pharmacy in Grand Rapids, MI, Eid speaks with pharmacy industry guests to educate and engage listeners about the profession.

Individuals with HIV have more QT interval variability than those without the disease, which may lead to the increased risk of sudden cardiac death.

Researchers may have found a way to stop the driving force at a molecular level behind acute lymphoblastic leukemia.